0000878088-12-000057.txt : 20121002 0000878088-12-000057.hdr.sgml : 20121002 20121002161308 ACCESSION NUMBER: 0000878088-12-000057 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20120928 FILED AS OF DATE: 20121002 DATE AS OF CHANGE: 20121002 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HAUGHEY THOMAS CENTRAL INDEX KEY: 0001272247 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-10827 FILM NUMBER: 121123584 MAIL ADDRESS: STREET 1: 300 TICE BOULDVARD STREET 2: C/O PAR PHARMACEUTICAL CITY: WOODCLIFF LAKE STATE: NJ ZIP: 07677 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PAR PHARMACEUTICAL COMPANIES, INC. CENTRAL INDEX KEY: 0000878088 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 223122182 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 TICE BOULEVARD CITY: WOODCLIFF LAKE STATE: NJ ZIP: 07677 BUSINESS PHONE: 201-802-4000 MAIL ADDRESS: STREET 1: 300 TICE BOULEVARD CITY: WOODCLIFF LAKE STATE: NJ ZIP: 07677 FORMER COMPANY: FORMER CONFORMED NAME: PHARMACEUTICAL RESOURCES INC DATE OF NAME CHANGE: 19940526 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2012-09-28 1 0000878088 PAR PHARMACEUTICAL COMPANIES, INC. PRX 0001272247 HAUGHEY THOMAS 300 TICE BOULDVARD C/O PAR PHARMACEUTICAL WOODCLIFF LAKE NJ 07677 1 1 0 0 President Common Stock 2012-09-28 4 D 0 69648 50 D 0 D Common Stock 2012-09-28 4 D 0 900 50 D 0 I By Self as Guardian for Children Performance Stock Units 2012-09-28 4 D 0 25438 50 D Common Stock 25438 0 D Restricted Stock Units 2012-09-28 4 D 0 25438 50 D Common Stock 25438 0 D Stock Option (right to buy) 42.14 2012-09-28 4 D 0 14951 7.86 D 2015-01-05 Common Stock 14951 0 D Stock Option (right to buy) 33.62 2012-09-28 4 D 0 7496 16.38 D 2016-01-08 Common Stock 7496 0 D Stock Option (right to buy) 24.27 2012-09-28 4 D 0 13200 25.73 D 2017-03-21 Common Stock 13200 0 D Stock Option (right to buy) 10.99 2012-09-28 4 D 0 34290 39.01 D 2018-11-17 Common Stock 34290 0 D Stock Option (right to buy) 13.06 2012-09-28 4 D 0 44926 36.94 D 2019-01-07 Common Stock 53599 8673 D Stock Option (right to buy) 13.06 2012-09-28 4 D 0 8673 D 2019-01-07 Common Stock 8673 0 D Stock Option (right to buy) 27.71 2012-09-28 4 D 0 25262 D 2020-01-03 Common Stock 25262 0 D Stock Option (right to buy) 36.54 2012-09-28 4 D 0 17789 D 2021-01-05 Common Stock 17789 0 D Stock Option (right to buy) 32.76 2012-09-28 4 D 0 50875 D 2022-01-05 Common Stock 50875 0 D On Sept 28, 2012, certain affiliates of TPG Capital, L.P.("TPG") acquired the Issuer (the "Merger") pursuant to that certain merger agreement, as of July 14, 2012, by and among the Issuer, Sky Growth Holdings Corporation ("Parent") and Sky Growth Acquisition Corporation ("Merger Sub"). In connection with the Merger, TPG acquired all of the outstanding shares of the Issuer's Common Stock at a price of $50 per share, in cash. In addition, all outstanding deferred unit awards, performance stock units, restricted stock units and options (other than such awards held by certain employees that were exchanged for awards of Parent's stock) were cancelled upon the closing of the Merger in exchange for cash payments at a price of $50 per unit or option share (less the exercise price in the case of options), payable without interest and less any required withholding taxes. This transaction is more fully described in the Issuer's Proxy Statement filed with the SEC on Aug 27, 2012, as amended. The vesting of this performance stock unit (which was to vest upon the achievement of certain predetermined financial, operational and strategic goals over the three year period ending December 31, 2015) was accelerated upon the change of control effective as of the approval of the Merger by the stockholders of the Issuer based on the target number of units awarded. This performance stock unit was cancelled upon the closing of the Merger in exchange for a cash payment of $50.00 per unit. The vesting of this restricted stock unit (which provided for vesting on January 5, 2016) was accelerated upon the change of control effective as of the approval of the Merger by the stockholders of the Issuer. This restricted stock unit was cancelled upon the closing of the Merger in exchange for a cash payment of $50.00 per unit. The options, all of which were exercisable, were cancelled upon the closing of the Merger in exchange for a cash payment equal to the number of shares underlying such options multiplied by the difference between the exercise price of such options and the Merger consideration of $50.00 per share. The vesting of certain of these options was accelerated upon the change of control effective as of the approval of the Merger by the stockholders of the Issuer and these options were cancelled upon the closing of the Merger in exchange for a cash payment equal to the number of shares underlying such options multiplied by the difference between the exercise price of such options and the Merger consideration of $50.00 per share. The vesting of certain of these options was accelerated upon the change of control effective as of the approval of the Merger by the stockholders of the Issuer and these options were exchanged for options to purchase 427,174 shares of Parent's stock at an exercise price of $.25 per share. The vesting of certain of these options was accelerated upon the change of control effective as of the approval of the Merger by the stockholders of the Issuer and these options were exchanged for options to purchase 750,787 shares of Parent's stock at an exercise price of $.25 per share. The vesting of certain of these options was accelerated upon the change of control effective as of the approval of the Merger by the stockholders of the Issuer and these options were exchanged for options to purchase 319,253 shares of Parent's stock at an exercise price of $.25 per share. The vesting of certain of these options was accelerated upon the change of control effective as of the approval of the Merger by the stockholders of the Issuer and these options were exchanged for options to purchase 1,169,447 shares of Parent's stock at an exercise price of $.25 per share. LIMITED POWER OF ATTORNEY: KNOW ALL MEN BY THESE PRESENTS, that the undersigned does hereby constitute and appoint MARIAN E. GUSTAFSON with full power to act, as his/her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him/her and in his/her name, place and stead, in any and all capacities, and to do any and all acts and things in his/her name and on his/her behalf, to execute any and all documents and instruments, which said attorney-in-fact may deem necessary or advisable to enable him/her to comply with the reporting requirements pursuant to Section 16 of the Securities Exchange Act of 1934, as amended, including but not limited to Form 4 Statement of Changes in Beneficial Ownership and Form 5 Annual Statement of Changes in Beneficial Ownership, relating to his/her ownership in Par Pharmaceutical Companies, Inc. (the "Company") for the period October 1, 2012 through and including September 30, 2013; and to file the same, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that the said attorney-in-fact and agent may lawfully do or cause to be done by virtue thereof./s/ Thomas J. Haughey Sept. 4, 2012 /s/ Marian E. Gustafson for Thomas J. Haughey 2012-10-02